Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why

Synaptogenix, Inc. (NASDAQ:SNPXGet Free Report) shares were down 0.3% during mid-day trading on Wednesday . The stock traded as low as $2.80 and last traded at $2.90. Approximately 5,379 shares traded hands during trading, a decline of 57% from the average daily volume of 12,482 shares. The stock had previously closed at $2.91.

Synaptogenix Trading Down 0.3 %

The firm has a 50-day moving average of $3.15 and a 200 day moving average of $3.10.

Institutional Investors Weigh In On Synaptogenix

A hedge fund recently bought a new stake in Synaptogenix stock. Geode Capital Management LLC purchased a new position in shares of Synaptogenix, Inc. (NASDAQ:SNPXFree Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix at the end of the most recent quarter. Institutional investors and hedge funds own 10.34% of the company’s stock.

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Featured Articles

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.